KZIA 250117 5.00C (KZIA250117C5000) Stock Options, News & Quotes

US OptionsDetailed Quotes

KZIA250117C5000

Watchlist

0.20
-0.41-67.21%

15min DelayClose Dec 20 16:00 ET

0.55High0.20Low

Intraday

5D
Daily

News

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium
Yahoo FinanceDec 11 08:00 ET
Leptomeningeal Metastases Pipeline Development Research Report 2024, Featuring AstraZeneca, Kazia Therapeutics, and Plus Therapeutics
Yahoo FinanceDec 5 10:38 ET
Kazia Therapeutics | 20-F: FY2024 Annual Report
SECNov 15 16:10 ET · Announcements
Kazia Therapeutics Secures Nasdaq Compliance
TipRanksNov 12 10:40 ET
Express News | Kazia Therapeutics -Got Letter From Nasdaq Informing Co Has Regained Compliance With Minimum Bid Price Requirement for Continued Listing
ReutersNov 12 10:09 ET
Kazia Therapeutics Management to Meet With Maxim
TipRanksNov 10 17:10 ET

Comments

Jaguar8

Dec 11 07:24

NEWS

$Kazia Therapeutics (KZIA.US)$
Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium
Wednesday, 11th December at 8:00 am
SYDNEY, Dec. 11, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development, announced that data from two abstracts will be presented at the San Antonio Breast Cancer Symposium ...